These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Safety of antisense oligonucleotide and siRNA-based therapeutics. Chi X; Gatti P; Papoian T Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625 [TBL] [Abstract][Full Text] [Related]
26. [Antisense therapies for neurological diseases]. Pulst SM Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208 [TBL] [Abstract][Full Text] [Related]
27. [Oligonucleotide therapeutics - an emerging novel class of compounds]. Wacheck V Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803 [TBL] [Abstract][Full Text] [Related]
28. Drug Discovery Perspectives of Antisense Oligonucleotides. Kim Y Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Goga A; Stoffel M Nat Rev Drug Discov; 2022 Jun; 21(6):417-439. PubMed ID: 35210608 [TBL] [Abstract][Full Text] [Related]
30. Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. Synofzik M; van Roon-Mom WMC; Marckmann G; van Duyvenvoorde HA; Graessner H; Schüle R; Aartsma-Rus A Nucleic Acid Ther; 2022 Apr; 32(2):83-94. PubMed ID: 34591693 [TBL] [Abstract][Full Text] [Related]
31. Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation. Sun Y; Zhao Y; Zhao X; Lee RJ; Teng L; Zhou C Molecules; 2017 Oct; 22(10):. PubMed ID: 29027965 [TBL] [Abstract][Full Text] [Related]
33. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117 [TBL] [Abstract][Full Text] [Related]
34. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases. Holm A; Hansen SN; Klitgaard H; Kauppinen S RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908 [TBL] [Abstract][Full Text] [Related]
35. Noninvasive delivery of oligonucleotide by penetratin-modified polyplexes to inhibit protein expression of intraocular tumor. Tai L; Liu C; Jiang K; Chen X; Wei G; Lu W; Pan W Nanomedicine; 2017 Aug; 13(6):2091-2100. PubMed ID: 28435135 [TBL] [Abstract][Full Text] [Related]
36. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Yu B; Mao Y; Bai LY; Herman SE; Wang X; Ramanunni A; Jin Y; Mo X; Cheney C; Chan KK; Jarjoura D; Marcucci G; Lee RJ; Byrd JC; Lee LJ; Muthusamy N Blood; 2013 Jan; 121(1):136-47. PubMed ID: 23165478 [TBL] [Abstract][Full Text] [Related]
37. Nonviral delivery systems for antisense oligonucleotide therapeutics. Huang S; Hao XY; Li YJ; Wu JY; Xiang DX; Luo S Biomater Res; 2022 Sep; 26(1):49. PubMed ID: 36180936 [TBL] [Abstract][Full Text] [Related]
38. Reduction of liver tumor necrosis factor-alpha expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis. Dong L; Zuo L; Xia S; Gao S; Zhang C; Chen J; Zhang J J Gene Med; 2009 Mar; 11(3):229-39. PubMed ID: 19189285 [TBL] [Abstract][Full Text] [Related]